Osteopontin as a potential diagnostic biomarker for ovarian cancer

JAMA

Volumn 287, Issue 13, 2002, Pages 1671-1679

  Kim, Jae Hoon ^a,b   Skates, Steven J ^b,c,d   Uede, Toshimitsu ^e   Wong, Kwong Kwok ^f   Schorge, John O ^g   Feltmate, Colleen M ^b   Berkowitz, Ross S ^b,c,d   Cramer, Daniel W ^b,c,d   Mok, Samuel C ^b,d  

^a The Catholic University of Korea   (South Korea)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d DANA FARBER HARVARD CANCER CENTER   (United States)

^e HOKKAIDO UNIVERSITY   (Japan)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; MESSENGER RNA; OSTEOPONTIN; PARAFFIN; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER EPIDEMIOLOGY; CONTROLLED STUDY; DNA MICROARRAY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY DISEASE; PLASMA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS;

EID: 0037012469     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.13.1671     Document Type: Article

References (48)

1. Cancer statistics
2. Cancer statistics, 1999
3. In vivo gene expression profile analysis of human breast cancer progression
4. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis
5. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system
6. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray
7. Tissue microarrays for high-throughput molecular profiling of tumor specimens
8. Delineation of prognostic biomarkers in prostate cancer
9. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs)
10. Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women
11. A case-control study of galactose consumption and metabolism in relation to ovarian cancer
12. Prostasin, a potential serum marker for ovarian cancer
13. Real time quantitative PCR
14. Absolute and relative quantitation
15. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers
16. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers
17. Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer
18. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine
19. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma
20. Serum and tissue measurements of CA72-4 in ovarian cancer patients
21. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors
22. Screening for ovarian cancer: A pilot randomised controlled trial
23. Altered processing of a major secreted phosphoprotein correlates with tumorigenicity in Rous sarcoma virus-transformed mammalian cells
24. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone
25. Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: Induction is stable at high, but not at low, cell densities
26. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene
27. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation
28. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR)
29. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins
30. Receptor-ligand interaction between CD44 and osteopontin (Eta-1)
31. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo
32. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo
33. A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis
34. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo
35. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells
36. Secretion of osteopontin by macrophages and its accumulation at tissue surfaces during wound healing in mineralized tissues
37. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma
38. Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer
39. Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma
40. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP)
41. Osteopontin: Possible role in prostate cancer progression
42. Expression of osteopontin and osteonectin in breast cancer
43. Osteopontin expression in a group of lymph node negative breast cancer patients
44. Co-expression of osteopontin and CD44v9 in gastric cancer
45. Osteopontin expression in cardiovascular diseases
46. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer
47. Differential osteopontin expression in lung cancer